Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Susan Lockhead"'
Autor:
Diane B. Hauze, Michael C. Sharp, Bheem M. Bhat, Paula Green, Colleen Milligan, Daniel M. Green, Jennifer Pirrello, Peter V.N. Bodine, Ronald L. Magolda, Adam M. Gilbert, Matthew D. Vera, Yogendra P. Kharode, Valerie E. Coleburn, Luciana De Araujo Felix, Mattew G. Bursavich, Nipa Alon, Jeanne J. Matteo, Jay Wrobel, Frederick J. Bex, Jeffrey C. Pelletier, Susan Lockhead, Joseph T. Lundquist, Richard J. Murrills, Ray Unwalla, Paul J. Yaworsky, Sally Selim, John F. Mehlmann, Ho-Sun Lam
Publikováno v:
Journal of Medicinal Chemistry. 52:6962-6965
A high-throughput screening campaign to discover small molecule leads for the treatment of bone disorders concluded with the discovery of a compound with a 2-aminopyrimidine template that targeted the Wnt beta-catenin cellular messaging system. Hit-t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26eacb52fff02ace8eb134ea084fe282
https://doi.org/10.1021/jm9014197
https://doi.org/10.1021/jm9014197
Autor:
Laura L. Carter, Barry S. Komm, Dharmesh Patel, Yanong D Wang, Yogendra P. Kharode, Shoichi Fukayama, Max Follettie, Jeanne J. Matteo, Jason Jussif, Vikki Spaulding, Yao-Bin Liu, Frank Boschelli, Giovan Lane, Yuchen Bai, Frederick J. Bex, Veronica Diesl, X. Jian Li, Richard J. Murrills, Colleen Milligan, Diane H. Boschelli, Peter V.N. Bodine, John C McKew, Jennifer M. Golas, Susan Lockhead, Jane Owens
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 340(3)
Src-null mice have higher bone mass because of decreased bone resorption and increased bone formation, whereas Abl-null mice are osteopenic, because of decreased bone formation. Compound I, a potent inhibitor of Src in an isolated enzyme assay (IC(50
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8220d8c757b207802a58b0d65b486413
https://pubmed.ncbi.nlm.nih.gov/22171089
https://pubmed.ncbi.nlm.nih.gov/22171089
Publikováno v:
Drug metabolism letters. 4(4)
Neratinib (HKI-272), an irreversible inhibitor of Her 2 tyrosine kinase, is currently in development as an alternative for first and second line therapy in metastatic breast cancer patients who overexpress Her 2. Following incubation of [(14)C]nerati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fa4df5c82fefd6793044383fcb9d4ad
https://pubmed.ncbi.nlm.nih.gov/20690900
https://pubmed.ncbi.nlm.nih.gov/20690900
Autor:
Abdul Mutlib, Appavu Chandrasekaran, Robert Espina, Xiao Xian Li-Chan, Peter M. Horwatt, Lin Deng, Jim Atherton, JoAnn Scatina, Steven Ross, Aram Oganesian, Linning Yu, Rasmy Talaat, Syed Ahmad, Jianyao Wang, Susan Lockhead
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 38(7)
The study was initiated as an observation of incomplete extraction recovery of N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide (HKI-272) from human plasma. The objective of this study was to 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46153f57406f7d499f378b35b9ee7dcf
https://pubmed.ncbi.nlm.nih.gov/20400660
https://pubmed.ncbi.nlm.nih.gov/20400660
Autor:
Puwen Zhang, Jeffrey A. Cohen, Jeffrey A. Kern, Terefenko Eugene Anthony, Susan Lockhead, Zhiming Zhang, Margaret LaCava, Eugene John Trybulski, Ray Unwalla, Richard C. Winneker, Jay E. Wrobel, Yuan Zhu, Andrew Fensome
Publikováno v:
Bioorganicmedicinal chemistry. 15(20)
We have recently discovered 5-(3-cyclopentyl-2-thioxo-2,3-dihydro-1H-benzimidazol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (14) as a potent, selective, and orally active non-steroidal progesterone receptor (PR) agonist. Compound 14 and its analog 13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55886393086de0b475ae609d537136a8
https://pubmed.ncbi.nlm.nih.gov/17681796
https://pubmed.ncbi.nlm.nih.gov/17681796
Autor:
Andrea Olland, Richard C. Winneker, Yuan Zhu, Ray Unwalla, Jeffrey I. Cohen, Puwen Zhang, Terefenko Eugene Anthony, Valerie Hudak, Karl Malakian, Jay Wrobel, Zhiming Zhang, Rajiv Chopra, Susan Lockhead, Scott Wolfrom, Reinhold H. W. Bender, James M. Wilhelm, Mark A. Collins, Andrew Fensome, Kristine Svenson
Publikováno v:
Journal of medicinal chemistry. 48(16)
Tanaproget represents a potential first-in-class nonsteroidal PR agonist for contraception with improved safety and side effect profiles versus currently available steroidal oral contraceptives. Additional SAR, biological activity, and structural inf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2c1474890c033be11e5a1fc25708ef1
https://pubmed.ncbi.nlm.nih.gov/16078826
https://pubmed.ncbi.nlm.nih.gov/16078826